99 related articles for article (PubMed ID: 36254099)
1. Initial Low-Dose Hydroxyurea and Anagrelide Combination in Essential Thrombocythemia: Comparable Response with Lower Toxicity.
Park YH; Mun YC; Lee S; Ahn Y
J Clin Med; 2024 May; 13(10):. PubMed ID: 38792442
[No Abstract] [Full Text] [Related]
2. Complete hematological and major molecular response through treatment with low-dose Interferon alpha 2a in high-risk polycythemia vera patient: a case report.
Driessen C; Noppen C; Boonen G; Drewe J
Clin Case Rep; 2021 Oct; 9(10):e04903. PubMed ID: 34631086
[TBL] [Abstract][Full Text] [Related]
3. Cytokine Profiling as a Novel Complementary Tool to Predict Prognosis in MPNs?
Hasselbalch HC
Hemasphere; 2020 Jun; 4(3):e407. PubMed ID: 32647805
[No Abstract] [Full Text] [Related]
4. Aging, Inflammation, and Comorbidity in Cancers-A General In Silico Study Exemplified by Myeloproliferative Malignancies.
Ottesen JT; Andersen M
Cancers (Basel); 2023 Sep; 15(19):. PubMed ID: 37835500
[TBL] [Abstract][Full Text] [Related]
5. JAK2 V617F allele burden in polycythemia vera: burden of proof.
Moliterno AR; Kaizer H; Reeves BN
Blood; 2023 Apr; 141(16):1934-1942. PubMed ID: 36745865
[TBL] [Abstract][Full Text] [Related]
6. Minimal residual disease or cure in MPNs? Rationales and perspectives on combination therapy with interferon-alpha2 and ruxolitinib.
Bjørn ME; Hasselbalch HC
Expert Rev Hematol; 2017 May; 10(5):393-404. PubMed ID: 28402197
[TBL] [Abstract][Full Text] [Related]
7. A novel integrated biomarker index for the assessment of hematological responses in MPNs during treatment with hydroxyurea and interferon-alpha2.
Dam MJB; Pedersen RK; Knudsen TA; Andersen M; Ellervik C; Larsen MK; Kjaer L; Skov V; Hasselbalch HC; Ottesen JT
Cancer Med; 2023 Feb; 12(4):4218-4226. PubMed ID: 36254099
[TBL] [Abstract][Full Text] [Related]
8. Perspectives on interferon-alpha in the treatment of polycythemia vera and related myeloproliferative neoplasms: minimal residual disease and cure?
Hasselbalch HC; Holmström MO
Semin Immunopathol; 2019 Jan; 41(1):5-19. PubMed ID: 30203226
[TBL] [Abstract][Full Text] [Related]
9. Second malignancies in hydroxyurea and interferon-treated Philadelphia-negative myeloproliferative neoplasms.
Hansen IO; Sørensen AL; Hasselbalch HC
Eur J Haematol; 2017 Jan; 98(1):75-84. PubMed ID: 27471124
[TBL] [Abstract][Full Text] [Related]
10. Interferon α-2b gains high sustained response therapy for advanced essential thrombocythemia and polycythemia vera with JAK2V617F positive mutation.
Huang BT; Zeng QC; Zhao WH; Li BS; Chen RL
Leuk Res; 2014 Oct; 38(10):1177-83. PubMed ID: 25069759
[TBL] [Abstract][Full Text] [Related]
11. A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia.
Mascarenhas J; Kosiorek HE; Prchal JT; Rambaldi A; Berenzon D; Yacoub A; Harrison CN; McMullin MF; Vannucchi AM; Ewing J; O'Connell CL; Kiladjian JJ; Mead AJ; Winton EF; Leibowitz DS; De Stefano V; Arcasoy MO; Kessler CM; Catchatourian R; Rondelli D; Silver RT; Bacigalupo A; Nagler A; Kremyanskaya M; Levine MF; Arango Ossa JE; McGovern E; Sandy L; Salama ME; Najfeld V; Tripodi J; Farnoud N; Penson AV; Weinberg RS; Price L; Goldberg JD; Barbui T; Marchioli R; Tognoni G; Rampal RK; Mesa RA; Dueck AC; Hoffman R
Blood; 2022 May; 139(19):2931-2941. PubMed ID: 35007321
[TBL] [Abstract][Full Text] [Related]
12. Genomic profiling of a randomized trial of interferon-α vs hydroxyurea in MPN reveals mutation-specific responses.
Knudsen TA; Skov V; Stevenson K; Werner L; Duke W; Laurore C; Gibson CJ; Nag A; Thorner AR; Wollison B; Hansen DL; Ellervik C; El Fassi D; de Stricker K; Ocias LF; Brabrand M; Bjerrum OW; Overgaard UM; Frederiksen M; Kristensen TK; Kruse TA; Thomassen M; Mourits-Andersen T; Severinsen MT; Stentoft J; Starklint J; Neuberg DS; Kjaer L; Larsen TS; Hasselbalch HC; Lindsley RC; Mullally A
Blood Adv; 2022 Apr; 6(7):2107-2119. PubMed ID: 34507355
[TBL] [Abstract][Full Text] [Related]
13. Data-driven analysis of the kinetics of the JAK2V617F allele burden and blood cell counts during hydroxyurea treatment of patients with polycythemia vera, essential thrombocythemia, and primary myelofibrosis.
Dam MJB; Pedersen RK; Knudsen TA; Andersen M; Skov V; Kjaer L; Hasselbalch HC; Ottesen JT
Eur J Haematol; 2021 Dec; 107(6):624-633. PubMed ID: 34411333
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
